[REVISION HISTORY]
South Korea GLP-1 obesity drug surge and illegal imports
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-07-30 15:53 UTC → 2026-08-24 02:04 UTC ·
added
removed
South Korea GLP‑1 GLP-1 obesity drug surge and illegal imports
Within ten months of their market launch in August 2023, GLP‑1 GLP-1 obesity medicines—including Maunzaro, Mounjaro and Wegovy—were prescribed more than 1.5 million times in South Korea. Monthly dispensing rose from under 2,000 prescriptions to over 273,000 by May 2024, a 14.7‑fold 14.7-fold increase. Over half of all prescriptions (about 53 %) 53%) went to patients in their 20s and 30s, with the 30‑year‑old 30-year-old segment the largest, while teenage use also climbed sharply, rising roughly 1.5‑fold 1.5-fold in the same period. The rapid uptake has prompted concerns about non‑medical non-medical and cosmetic use. Physicians report prescriptions often lack thorough assessment, and online chat groups circulate tips on obtaining the drugs and identifying permissive prescribers. Government action so far Lawmaker Han Ji-a of the People Power Party has urged a shift toward stricter management using DUR data, noting that government measures have been limited to adding warning labels, but lawmakers labels. In response to rising misuse, the Ministry of Food and Drug Safety has designated Wegovy and Mounjaro as ‘harmful drugs’ to prevent unauthorized individual imports. This follows a significant surge in illegal imports; the Korea Customs Service detected 4,155 cases in the first half of this year, a 3.5-fold increase compared to the total cases recorded throughout all of last year. Most illegal attempts (84.8%) involved international mail via overseas websites, though imports through travelers' personal belongings have urged tighter prescription‑management rules also risen. The Korea Customs Service now blocks these items regardless of quantity, and all intercepted products are reviewing whether subject to classify GLP‑1 agents as drugs with misuse risk, which would impose stricter prescribing and dispensing controls. total destruction.
Versions
- 2026-08-24 02:04 UTC South Korea GLP-1 obesity drug surge and illegal imports
- 2026-07-30 15:53 UTC South Korea GLP‑1 obesity drug surge
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.